Trial Profile
A Single-centre retrospective study of extended-release Levodopa/carbidopa (Rytary) in patients with Parkinson's disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Sep 2016
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- 27 Sep 2016 New trial record